Massive drug showdown: can a new pill beat river blindness for good?
NCT ID NCT07145736
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two drugs, ivermectin and moxidectin, to see which works better at controlling river blindness and other common infections like intestinal worms and scabies in Angola. Over 52,000 people in 20 village groups will receive one of the drugs once a year for four years. The goal is to find the best way to reduce these diseases in the community and help guide global treatment policies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASCARIS LUMBRICOIDES INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Villages in Andulo and Nharea Municipalities
RECRUITINGAndulo, Bíe Province, Angola
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a single pill cure scabies? new study tests three doses
- Concrete floors could slash child infections in bangladesh
- AI app aims to help frontline workers diagnose neglected skin diseases
- New study aims to find safe scabies treatment for toddlers
- New drug moxidectin put to the test against river blindness in massive safety trial
- Could a common parasite drug help young kids with scabies?